Category: 2021

Ryvu announces option to license inflammation program exercised by Galapagos NV

Read More

Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium

Read More

Ryvu Therapeutics Reports Q3 2021 Financial Results

Read More

Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Read More

Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

Read More

Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University

Read More

Ryvu Therapeutics Reports 2021 Half-Year Financial Results

Read More

Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

Read More

Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry

Read More

Ryvu Therapeutics to participate in upcoming global investor conferences

Read More

FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Read More

Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.

Read More

Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics

Read More

Ryvu Therapeutics among the founding members of 30% Club Poland

Read More

Discussion On Ryvu Data Presented at EHA 2021 – Conference Call

Read More

Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar

Read More

SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

Read More

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

Read More

Ryvu Therapeutics announces participation in the UBS 2021 Global Healthcare Virtual Conference and the Erste Group Innovation Conference 2021

Read More

Ryvu Therapeutics presents at STING- & TLR-Targeting Therapies Summit

Read More